Aljian Capital Management’s Gilead Sciences GILD Stock Holding History

Aljian Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$629K	Buy	4,514 +13	+0.3%	+$1.82K	0.13%	78
2025 Q4	$552K	Sell	4,501 -385	-8%	-$46.8K	0.11%	79
2025 Q3	$542K	Buy	4,886 +17	+0.3%	+$1.93K	0.11%	83
2025 Q2	$540K	Sell	4,869 -873	-15%	-$92.9K	0.12%	80
2025 Q1	$643K	Sell	5,742 -1	-0%	-$103	0.15%	76
2024 Q4	$530K	Buy	5,743 +28	+0.5%	+$2.52K	0.12%	76
2024 Q3	$479K	Buy	+5,715	New	+$436K	0.11%	79

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Aljian Capital Management's GILD Position: Q1 2026 in Review

Aljian Capital Management increased its Gilead Sciences (GILD) stake by 0.29% in Q1 2026, buying an estimated $1.82K and bringing the position to 4,514 shares worth $629K. The position accounts for 0.13% of the portfolio, ranked #78.

Aljian Capital Management first reported a position in GILD in Q3 2024 and has held it in 7 quarters since. The position peaked at $643K in Q1 2025. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Aljian Capital Management held 4,514 shares of Gilead Sciences worth $629K as of Q1 2026.
Aljian Capital Management bought 13 Gilead Sciences shares in Q1 2026, an estimated $1.82K.
Gilead Sciences made up 0.13% of Aljian Capital Management's portfolio in Q1 2026, its #78 holding.
Aljian Capital Management first reported a position in Gilead Sciences in Q3 2024 and has held it in 7 quarters since.
Aljian Capital Management's Gilead Sciences position peaked at $643K in Q1 2025.
2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Aljian Capital Management's 13F filing for Q1 2026, filed 29 Apr 2026.